BRPI0516953A - partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico - Google Patents

partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico

Info

Publication number
BRPI0516953A
BRPI0516953A BRPI0516953-4A BRPI0516953A BRPI0516953A BR PI0516953 A BRPI0516953 A BR PI0516953A BR PI0516953 A BRPI0516953 A BR PI0516953A BR PI0516953 A BRPI0516953 A BR PI0516953A
Authority
BR
Brazil
Prior art keywords
present
virus
vlp
modified
fusion protein
Prior art date
Application number
BRPI0516953-4A
Other languages
English (en)
Inventor
Martin Bachmann
Alain Tissot
Gary Jennings
Regina Renhofa
Paul Pumpes
Indulis Cielens
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of BRPI0516953A publication Critical patent/BRPI0516953A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PARTìCULAS DO TIPO VìRUS COMPREENDENDO UMA PROTEìNA DE FUSãO DA PROTEìNA DE REVESTIMENTO DE AP205 E UM POLIPEPTìDEO ANTIGENICO. A presente invenção está nos campos da medicina, imunologia, virologia e biologia molecular. A presente invenção provê uma composição compreendendo uma partícula do tipo vírus (VLP) modificada derivada de bacteriófago de RNA AP205. A invenção também provê um processo para a produção da VLP acima mencionada. A VLP modificada descrita na presente invenção é útil na produção de composições para indução de respostas imunes para a prevenção ou tratamento de doenças, distúrbios incluindo doenças infecciosas, alergias, cânceres e vício de fármaco. Além disso, a VLP modificada descrita na presente invenção é, em particular, útil para induzir eficientemente respostas autoimunes específicas, em particular respostas de anticorpo.
BRPI0516953-4A 2004-09-21 2005-09-21 partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico BRPI0516953A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61130804P 2004-09-21 2004-09-21
EP05105229 2005-06-14
PCT/EP2005/054721 WO2006032674A1 (en) 2004-09-21 2005-09-21 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide

Publications (1)

Publication Number Publication Date
BRPI0516953A true BRPI0516953A (pt) 2008-09-30

Family

ID=46307785

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516953-4A BRPI0516953A (pt) 2004-09-21 2005-09-21 partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico

Country Status (10)

Country Link
US (1) US20080292652A1 (pt)
EP (1) EP1791870A1 (pt)
JP (1) JP2008513035A (pt)
AU (1) AU2005286475A1 (pt)
BR (1) BRPI0516953A (pt)
CA (1) CA2580208A1 (pt)
MX (1) MX2007003171A (pt)
NZ (1) NZ554387A (pt)
RU (1) RU2409667C2 (pt)
WO (1) WO2006032674A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
EP2338510A1 (en) * 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
BRPI0408623A (pt) * 2003-03-26 2006-03-07 Cytos Biotechnology Ag conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
CA2588274A1 (en) 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
NZ554386A (en) 2004-10-25 2009-12-24 Cytos Biotechnology Ag Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof
US20100111995A1 (en) * 2005-06-14 2010-05-06 Cytos Biotechnology Ag Antigen conjugates and uses thereof
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
JP5484732B2 (ja) * 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
AU2007260236B2 (en) 2006-06-12 2013-05-16 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
JP5389662B2 (ja) 2006-12-12 2014-01-15 サイトス バイオテクノロジー アーゲー 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
WO2008074895A1 (en) * 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
CA2721657A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
WO2010122164A1 (en) 2009-04-23 2010-10-28 Cytos Biotechnology Ag VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
NZ596058A (en) * 2009-04-30 2013-08-30 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
NZ601729A (en) * 2010-03-29 2013-10-25 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
GB201121571D0 (en) * 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
BR112014020052B8 (pt) * 2012-02-16 2023-04-18 Vlp Therapeutics Llc Partícula do tipo vírus, composições, método de produção de anticorpo e uso da referida partícula
WO2015193143A1 (en) * 2014-06-18 2015-12-23 Morphosys Ag Fusion proteins and uses thereof
CN104255335B (zh) * 2014-08-24 2016-08-31 苗建军 一种吊放蔓用钳
RU2568872C1 (ru) * 2014-10-15 2015-11-20 Игорь Геннадьевич Сивов Лекарственное средство для лечения вирусного гепатита с
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
US10588953B2 (en) 2015-12-18 2020-03-17 Agilvax, Inc. Compositions and methods related to xCT peptides
AU2017256727B2 (en) * 2016-04-27 2022-09-29 ELANCO US, Inc. Treatment of canine atopic dermatitis
CN112500456B (zh) * 2020-12-02 2022-10-28 深圳赫兹生命科学技术有限公司 一种去势ap205病毒样颗粒亚单位疫苗
US20240189407A1 (en) 2021-04-12 2024-06-13 Saiba AG Modified virus-like particles of bacteriophage ap205
US20240156937A1 (en) * 2021-04-23 2024-05-16 Unm Rainforest Innovations Baceriophage virus-like particles vaccines for chlamydia trachomatis infections
CN114933639B (zh) * 2022-05-05 2023-12-29 中国农业科学院兰州兽医研究所 非洲猪瘟病毒p72N抗原表位蛋白及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP2196217A1 (en) * 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
NZ531534A (en) * 2001-10-05 2005-10-28 Cytos Biotechnology Ag Angiotensin peptides conjugated with a carrier comprising a virus-like particle
DK1441764T3 (da) * 2001-11-07 2009-01-26 Cytos Biotechnology Ag Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
ATE419007T1 (de) * 2001-11-07 2009-01-15 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
CA2488856A1 (en) * 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
PT1523329E (pt) * 2002-07-05 2013-10-08 Folia Biotech Inc Partícula viral adjuvante
JP4726483B2 (ja) * 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ

Also Published As

Publication number Publication date
JP2008513035A (ja) 2008-05-01
RU2409667C2 (ru) 2011-01-20
RU2007114956A (ru) 2008-10-27
EP1791870A1 (en) 2007-06-06
WO2006032674A1 (en) 2006-03-30
AU2005286475A1 (en) 2006-03-30
MX2007003171A (es) 2007-05-23
CA2580208A1 (en) 2006-03-30
US20080292652A1 (en) 2008-11-27
NZ554387A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
BRPI0516953A (pt) partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
HK1078880A1 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
Jegerlehner et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses
JP2015205881A5 (pt)
BRPI0408623A (pt) conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
BRPI0511751A (pt) usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
BR9915771A (pt) Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
HK1068355A1 (en) Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
ECSP034867A (es) MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
Tumban Bacteriophage virus-like particles: Platforms for vaccine design
WO2003059386A3 (en) Prion protein carrier-conjugates
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
UY31574A1 (es) Vacunas contra la malaria
Uwishema et al. The insight through the current immunotherapeutic guidelines for infectious diseases
MXPA04003900A (es) Disposiciones de antigenos para el tratamiento de enfermedades oseas.
JP2005512987A5 (pt)
김주형 et al. Virus-like Particle (VLP) Mediated Antigen Delivery as a Sensitization Tool of Experimental Allergy Mouse Models
BR112023020640A2 (pt) Partículas similares a vírus de bacteriófago ap205 modificadas
Fox et al. Emulsion-based vaccine adjuvants
BR0215013A (pt) Biomassa particulada de embrião aviário para a produção de antìgenos de vìrus
CY1116497T1 (el) Λειτουργικα ιομορφα σωματιδια γριπης (vlps)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.